• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tempus AI Inc.

    4/7/25 4:08:29 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    DEFA14A 1 d911583ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.   )

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    TEMPUS AI, INC.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    Your Vote Counts! ATTN: LEGAL TEMPUS AI, INC. 600 WEST CHICAGO AVENUE, SUITE 510 CHICAGO, IL 60654 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the Notice and Proxy Statement and Annual Report, and to obtain directions to attend the meeting, go to: www.proxyvote.com. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. TEMPUS AI, INC. 2025 Annual Meeting of Stockholders Vote by May 19, 2025 10:59 PM Central Time You invested in TEMPUS AI, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 20, 2025. Vote Virtually at the Meeting* May 20, 2025 1:30 PM Central Time Virtually at: www.virtualshareholdermeeting.com/TEM2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V68265-P28862 Get informed before you vote View the Notice of Annual Meeting, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


    LOGO

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V68266-P28862 1. To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal. For Nominees: 01) Eric Lefkofsky 02) Peter J. Barris 03) Eric D. Belcher 04) Jennifer A. Doudna 05) David R. Epstein 06) Wayne A.I. Frederick, M.D. 07) Scott Gottlieb, M.D. 08) Theodore J. Leonsis 09) Nadja West, M.D. 2. To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To approve the reincorporation of the Company from the State of Delaware to the State of Nevada by conversion. For NOTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    More analyst ratings

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

    New study published in Nature Communications builds on Ambry's contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), today announced its contribution to new research leveraging Multiplexed Assays of Variant Effect (MAVEs) studies to advance interpretation of hereditary cancer-linked genetic variants, published in Nature Communications. Led by researchers at Leiden University Medical Center in the Netherlands and supported by Ambry's extensive clinical data, this study revealed previously unfounded missense path

    2/4/26 7:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

    Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the company's commitment to diagnostic accuracy. A decade ago, in an industry first, Ambry Genetics pioneered paired DNA/RNA testing for hereditary cancer and continues to be among the only laboratories offering RNA testing insights across both hereditary cancer and exome testing. Ambry Genetics first implemented RNA testing in 2016 as part of a research and validation pilot and subseq

    2/2/26 7:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift

    Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by "federated learning" models that use high-frequency sensing to collapse development timelines from years into months[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Recursion Pharmaceutical

    1/29/26 9:25:00 AM ET
    $LLY
    $RXRX
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Tempus AI with a new price target

    Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

    12/2/25 8:35:17 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by TD Cowen with a new price target

    TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00

    10/21/25 7:15:53 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Canaccord Genuity initiated coverage on Tempus AI with a new price target

    Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00

    10/20/25 8:04:09 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    1/28/26 4:21:30 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    1/12/26 6:05:18 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    12/18/25 4:39:19 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Epstein David R sold $21,982 worth of shares (370 units at $59.41), decreasing direct ownership by 1% to 26,051 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    2/4/26 4:30:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $10,899,207 worth of shares (166,250 units at $65.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    1/30/26 4:15:08 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Operating Officer Fukushima Ryan sold $321,300 worth of shares (5,000 units at $64.26) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    1/7/26 6:25:17 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Second Quarter 2025 Financial Results on August 8

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

    7/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology